Terns Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-90.21	-60.35	-50.16	-29.35	-68.61	Upgrade
Depreciation & Amortization	0.88	1.03	0.51	0.39	0.2	Upgrade
Share-Based Compensation	25.54	10.77	8.15	1.69	0.67	Upgrade
Other Operating Activities	-3.6	-0.56	-0.33	8.16	1.53	Upgrade
Operating Cash Flow	-67.39	-49.11	-41.83	-29.81	-66.22	Upgrade
Capital Expenditures	-0.05	-0.28	-0.34	-0.58	-0.9	Upgrade
Change in Investments	-37.94	-22	-119.36	7.28	-2.96	Upgrade
Investing Cash Flow	-37.99	-22.27	-119.7	6.69	-3.86	Upgrade
Share Issuance / Repurchase	42.3	167.5	137.28	0.12	0.03	Upgrade
Debt Issued / Paid	0	0	-12.88	16.88	0.06	Upgrade
Other Financing Activities	-0.34	-0.4	10	68.52	-0.02	Upgrade
Financing Cash Flow	41.95	167.1	134.39	85.52	0.06	Upgrade
Exchange Rate Effect	0.12	-0.18	-0.03	0.08	-0.13	Upgrade
Net Cash Flow	-63.31	95.54	-27.16	62.48	-70.15	Upgrade
Free Cash Flow	-67.44	-49.38	-42.17	-30.39	-67.12	Upgrade
Free Cash Flow Margin	-	-	-4216.70%	-	-	Upgrade
Free Cash Flow Per Share	-0.95	-1.37	-1.86	-106.58	-366.26	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).